Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of the pharmacokinetics of nevirapine and the incidence of nevirapine resistance mutations in HIV-infected women receiving a single intrapartum dose of nevirapine with the concomitant administration of zidovudine/didanosine or zidovudine/didanosine/lopinavir/ritonavir

Trial Profile

Phase II study of the pharmacokinetics of nevirapine and the incidence of nevirapine resistance mutations in HIV-infected women receiving a single intrapartum dose of nevirapine with the concomitant administration of zidovudine/didanosine or zidovudine/didanosine/lopinavir/ritonavir

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Nevirapine (Primary) ; Didanosine; Lopinavir/ritonavir; Zidovudine
  • Indications HIV infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Dec 2012 Primary drug tag added, completion date updated
    • 06 Dec 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top